Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen ... The Providence Journal The report also finds that novel late-stage emerging disease-modifying therapies (DMTs) for the treatment of MS--Genzyme/Bayer HealthCare's Lemtrada, Biogen Idec/AbbVie's daclizumab and Roche/Genentech's ocrelizumab--will generally be reserved for ... |
